DOCSLIB.ORG

Severe Combined Immunodeficiency (SCID) Associated Neutropenia: a Lesson from Arch Dis Child: First Published As 10.1136/Adc.74.4.340 on 1 April 1996

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Severe Combined Immunodeficiency (SCID) Associated Neutropenia: a Lesson from Arch Dis Child: First Published As 10.1136/Adc.74.4.340 on 1 April 1996 340 Archives ofDisease in Childhood 1996; 74: 340-342 Severe combined immunodeficiency (SCID) associated neutropenia: a lesson from Arch Dis Child: first published as 10.1136/adc.74.4.340 on 1 April 1996. Downloaded from monozygotic twins Tim Niehues, Klaus Schwarz, Marion Schneider, Horst Schroten, Elisabeth Schr6der, Volker Stephan, Volker Wahn Abstract non-genetic aetiology and requires specific A case of severe combined immuno- initial management. deficiency (SCID) in monozygotic twin sisters was detected at 3 months of age with neutropenia in one twin and a normal Case reports differential count in the other. The CASE 1 neutropenic twin, suffering from severe Twin I was referred to our clinic at the age of skin ulcers, was successfully treated with 3 months with a history of fever, diarrhoea, granulocyte colony stimulating factor (G- and deep skin ulcerations; Pseudomonas CSF). Discordant occurrence of neutro- aeruginosa and enterococci were detectable on penia in identical twins shows that there culture. After an apparently normal pregnancy may be a non-genetic cause for the the girl and her twin sister (case 2) had been neutropenia in SCID. Suppression of born to healthy, consanguineous Turkish myelopoiesis was probably induced by parents. A 2 year old sister is healthy. On activated maternal T cells. The neutro- admission twin 1 was in a good general condi- penia in this case may thus be classified as tion with a weight of 5500 g (25th centile for SCID associated neutropenia, as opposed Turkish girls). Physical examination revealed to reticular dysgenesis, in which the several deep skin ulcerations on both thighs neutropenia is G-CSF refractory and is each at least 2x2 cm in size. A complete blood most probably caused by a genetic stem count showed a decreased haemoglobin level cell defect. A response to G-CSF in a (7.0 g/dl) and packed cell volume (22%), a neutropenic child with SCID can be clini- normal platelet count (326 000/pAl) and 1600 cally beneficial and might help to distin- leucocytes/,ul with a differential blood count of guish between G-CSF unresponsive 77% lymphocytes, 7% monocytes, 10% http://adc.bmj.com/ reticular dysgenesis and G-CSF respon- banded cells, and 6% polymorphonuclear sive SCID associated neutropenia. neutrophils (absolute neutrophil count: (Arch Dis Child 1996; 74: 340-342) 256/,ul). Cord blood results were not available. Antigranulocyte antibodies were not detected. Keywords: severe combined immunodeficiency (SCID), neutropenia, granulocyte colony stimulating The bone marrow showed a developmental factor (G-CSF). arrest at the stage of promyelocytes. Because the girl developed chronic rotavirus infection, was of on September 30, 2021 by guest. Protected copyright. University of B and T cell function evaluated. Levels Dusseldorf, immunoglobulins were low (IgG <91 mg/dl; Dusseldorf, Germany The association of severe combined immuno- IgM <14 mg/dl; IgA <8 mg/dl). Mature T cells were with an Department of deficiency (SCID) with congenital agranulocy- markedly decreased, Paediatrics tosis has been defined as reticular dysgenesis.1 increased relative percentage of B cells. The T Niehues Consistent with a genetic stem cell defect the complete surface marker profile is given in the H Schroten report described monozygotic twins table. Peripheral blood B and T cells were V Stephan original V Wahn with a complete absence of both neutrophils in separated immunomagnetically and T cells peripheral blood and myelopoietic stem cells in were identified as being of maternal origin by Department of the bone marrow. In contrast to the original HIA typing. The response of peripheral blood Transfusion Medicine M Schneider report, further cases described as reticular dys- lymphocytes to mitogens was markedly genesis showed variable numbers of neutro- decreased (table). The thymus could barely be Department of Human phils in peripheral blood and cells of the detected by sonography. Adenosine deaminase Genetics E Schr6der myelopoietic lineage at all maturational stages and purine nucleoside phosphorylase levels in bone marrow.2 3 Ownby et al even observed were normal. Severe B and T cell dysfunction University of Ulm, a variable degree of myeloid deficiency in led to the diagnosis of SCID. Ulm, Germany brothers, which makes a genetic stem cell The skin infections and ulcers barely Department of defect unlikely.2 Thus the aetiology of the responded to different intravenous antibiotic Paediatrics II neutropenia and the precise role of SCID and regimens. Therefore, 1 pug/kg of granulocyte K Schwarz neutropenia in the syndrome of reticular dys- colony stimulating factor (G-CSF) (Neupo- Correspondence to: genesis are not clear. gen, Amgen, Munich) was given subcuta- Prof Dr med Volker Wahn, Zentrum fuir We had the unique opportunity to study two neously on alternate days. A response was Kinderheilkunde der genetically identical individuals with SCID. noted on day 6 and neutrophil counts above Heinrich Heine Universitat Dusseldorf, Moorenstr 5, Only one twin presented with severe neutro- 2000/pul could be maintained. Ulcers com- 40225 Dusseldorf, Gerrnany. penia, showing that there is an initial presenta- pletely healed within two weeks. After with- Accepted 12 December 1995 tion of neutropenia in SCID which has a drawal of G-CSF, neutrophil counts again fell Severe combined immunodeficiency associated neutropenia 341 Immunological studies. Surface marker profile and mitogen reaction, and severe failure to thrive requiring response. Numbers indicate percentages oftotal peripheral blood lymphocytes staining with each marker byflow parenteral nutrition. cytometry or counts per minute (cpm) in the thymidine Arch Dis Child: first published as 10.1136/adc.74.4.340 on 1 April 1996. Downloaded from incorporation assay Discussion Twin I Twin H Control We have described genetically identical twins T and B cell markers with different phenotypes of SCID. Both twins CD3+ 30 19 87 CD4+ 13 1 58 displayed clinical as well as laboratory findings CD8+ 12 11 25 consistent with SCID. The most surprising CD20+ 51 67 6 finding was that only one twin was severely NK cell markers CD56/CD3- 6 1 5 neutropenic at presentation, although genetic Adhesion markers identity was demonstrated by DNA finger- CD2+ 35 19 92 printing. A possible alloimmune aetiology for CD1 la 94 97 97 CD18 96 96 100 the neutropenia was evaluated but no Activation marker/HLA expression antigranulocytic antibodies were detected. CD4/HLA-DR+ 11 0 1 Cellular immune mechanisms involving CD8/HLA-DR+ 8 10 0 HLA-ABC 99 95 100 maternal T cells were not further analysed. An Mitogen response (cpm) infectious cause could not entirely be excluded Medium alone 470 200 120 but seemed unlikely because neutropenia PHA 1380 1750 33940 OKT3 210 920 24000 recurred when G-CSF was discontinued, at a PWM 1700 160 31320 time when there was no clinical or laboratory SAC 2100 390 4820 evidence of infection. PHA=phytohaemagglutinin: PWM=pokeweed mitogen; It is well known that materno-fetal trans- SAC=staphylococcal protein A of Cowan I strain. fusion of T cells can be demonstrated in more than 50 per cent of patients with SCID.5 We below 500/pl within five days. As dependence believe that suppression of myelopoeisis in our on G-CSF was documented, treatment was case was most probably explained by a GvH continued until bone marrow transplantation. reaction caused by maternal T cells. As Desquamative exanthema developed on maternal T cells were found in both children, it hands, feet, face, and skull. As this was associ- seems likely that there were major differences ated with a rise in transaminases it was felt in the effector functions of maternal T cells most likely to be the result of graft versus host between the twins. In the neutropenic twin I a (GvH) reaction caused by maternal T cells. much stronger activation ofT cells (percentage During more than two months of hospital of HLA-DR+ T cells, see the table) was inpatient care before bone marrow transplan- observed. There was indirect evidence that tation our patient had severe failure to thrive. haematopoetic suppression also involved After the decision to carry out a bone marrow erythropoiesis, as routine evaluation of the transplant had been made, a central venous anaemia did not reveal any other cause, and http://adc.bmj.com/ catheter was inserted and parenteral nutrition the anaemia persisted, with haemoglobin con- given. centrations between 6 and 8 g/dl. In the original report describing reticular dysgenesis it was stated that there may be CASE 2 several grades of severity. Severe cases of Twin II was referred to our clinic one day after neutropenia in SCID resembling the original her twin sister for treatment of pneumonia. On report usually present at birth or in the first on September 30, 2021 by guest. Protected copyright. admission she weighed 4500 g (below 10th week, with almost no detectable neutrophils; centile for turkish girls) but was normal on these cases are fatal within days to weeks.1 6 7 physical examination. Laboratory investiga- Attempts to treat a severe case and her sister tions on admission were also normal except for using G-CSF (4-30 ,ug/kg) failed. A genetic a moderately increased y glutamyl transferase stem cell defect seems likely in these cases and an increased leucocyte count (24 300/,l because myelopoiesis was resistant to G-CSF with a normal differential count), as well as a in vivo as well as in the absence of maternal T slightly raised C reactive protein (1 8 mg/dl). cells in vitro.7 Pneumonia was confirmed by chest x ray. After In the most recent report of reticular dys- treatment with intravenous antibiotics she genesis, treatment with granulocyte macro- made a rapid recovery from the pneumonia. phage colony stimulating factor (GM-CSF) When the diagnosis of SCID was established in resulted in reconstitution of normal neutrophil twin I we also evaluated twin II for possible counts.3 A difference in stem cell sensitivity to immunodeficiency.
Load more

Recommended publications
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Immune Cellular Evaluation Following Newborn Screening for Severe T
    In this issue: Clinical flow cytometry in 2019 This is a Platinum Open Access Journal distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Immune cellular evaluation following newborn screening for severe T and B cell lymphopenia Johannes Wolf1,2, Karolin Dahlenburg3, Stephan Borte2,4 1 Municipal Hospital St. Georg Leipzig, Academic Teaching Hospital of the University Leipzig, Department of Laboratory Medicine and Microbiology, Leipzig, Germany 2 Immuno Deficiency Center Leipzig (IDCL) at Hospital St. Georg Leipzig, Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency Diseases, Leipzig, Germany 3 Faculty of Medicine, University Leipzig, Germany 4 Municipal Hospital St. Georg Leipzig, Academic Teaching Hospital of the University Leipzig, Department of Pediatrics, Leipzig, Germany ARTICLE INFO ABSTRACT Corresponding author: Newborn screening (NBS) for severe T and/or B cell Stephan Borte, MD, PhD Immuno Deficiency Center Leipzig (IDCL) lymphopenia to identify neonates with severe com- Hospital St. Georg Leipzig bined immunodeficiencies (SCID) or agammaglob- Delitzscher Strasse 141 ulinemia rapidly after birth has paved its way into D-04129 Leipzig clinical practice. Debate exists on the concept and Germany Phone: +49 341 909 4478 strategy for rapid verification and stratification of the E-mail: [email protected] cellular immune status of positively screened infants. We provide impulses for harmonization of flow cyto- Key words: newborn screening, T cell lymphopenia, metric approaches to allow rapid integration in the B cell lymphopenia, severe combined growing number of immunological laboratories in- immunodeficiency volved in follow-up and subdivision of SCID and non- Acknowledgement: SCID entities.
    [Show full text]
  • Blueprint Genetics Severe Combined Immunodeficiency Panel
    Severe Combined Immunodeficiency Panel Test code: IM0101 Is a 80 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of combined immunodeficiencies. The genes on this panel are included in the Primary Immunodeficiency Panel. About Severe Combined Immunodeficiency Severe combined immunedeficiencies (SCIDs) are a group of primary immunodeficiencies characterized by specific mutations in genes of T and B-lymphocyte systems and leading to little or no immune response. Different subtypes of SCIDs are characterized and subdivided by the presence of circulating T and B cells. T cells are absent or markedly decreased in the most types, but levels of B cells vary. In addition, both of these disease subgroups (T-B+ and T-B-) can occur with or without NK cells. Patients with SCID are susceptible to recurrent infections that can be fatal. The worldwide prevalence of SCID is estimated to be at least 1:100,000 births, while some genetically more homogenous populations may show markedly increased numbers. Mutations in IL2RG are the most common reason for SCIDs, explaining approximately 50% of all cases and close to 100% of X-linked cases. Availability 4 weeks Gene Set Description Genes in the Severe Combined Immunodeficiency Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ADA Severe combined immunodeficiency due to adenosine deaminase AR 49 93 deficiency AK2 Reticular dysgenesis AR 14 17 ATM Breast cancer, Ataxia-Telangiectasia AD/AR 1047 1109 BCL11B Immunodeficiency
    [Show full text]
  • Investigations on the Molecular Biology of Human Adenylate
    Ulm University Medical Center Institute for Transfusion Medicine Prof. Dr. med. Hubert Schrezenmeier Investigations on the Molecular Biology of Human Adenylate Kinase 2 Deficiency (Reticular Dysgenesis) and the Establishment and Characterisation of an Adenylate Kinase 2-deficient Mouse Model Dissertation to obtain the doctoral degree of Human Biology (Dr. biol. hum.) of the Medical Faculty of Ulm University Rebekka Waldmann Ulm 2017 Amtierender Dekan: Prof. Dr. rer. nat. Thomas Wirth 1. Berichterstatter: Prof. Dr. med. Hubert Schrezenmeier 2. Berichterstatter: PD Dr. med. Manfred Hönig Tag der Promotion: 13.04.2018 Index Index INDEX OF ABBREVIATIONS ........................................................................................................................... I 1 INTRODUCTION ..................................................................................................................................... 1 1.1 SEVERE COMBINED IMMUNODEFICIENCIES (SCIDS) ........................................................................................ 1 1.2 RETICULAR DYSGENESIS ............................................................................................................................. 2 1.3 ADENYLATE KINASES ................................................................................................................................. 3 1.4 IMMUNODEFICIENT MOUSE MODELS ........................................................................................................... 7 1.5 AIM OF THE STUDY ..................................................................................................................................
    [Show full text]
  • 1 Reticular Dysgenesis
    Reticular Dysgenesis: International Survey on Clinical Presentation, Transplantation and Outcome Short Title: International Survey on Reticular Dysgenesis Authors: Manfred Hoenig1, Chantal Lagresle-Peyrou2, Ulrich Pannicke3, Luigi D. Notarangelo4, Fulvio Porta5, Andrew. R. Gennery6, Mary Slatter6, Morton J. Cowan7, Polina Stepensky8, Hamoud Al-Mousa9, Daifulah Al-Zahrani10, Sung-Yun Pai11, Waleed Al Herz12, Hubert B. Gaspar13, Paul Veys13, Koichi Oshima14, Kohsuke Imai15, Hiromasa Yabe16, Leonora M. Noroski17, Nico M. Wulffraat18, Karl-Walter Sykora19, Pere Soler-Palacin20, Hideki Muramatsu21, Mariam Al Hilali22, Despina Moshous23, Klaus-Michael Debatin1, Catharina Schuetz1, Eva-Maria Jacobsen1, Ansgar S. Schulz1, Klaus Schwarz3, Alain Fischer23, Wilhelm Friedrich1, Marina Cavazzana2, on behalf of the EBMT Inborn Errors Working Party Institutions: 1 University Medical Center Ulm, Department of Pediatrics, Ulm, Germany; 2 Biotherapy Clinical Investigation Center, Hôpital Necker Enfants Malades, Paris, France; 3 Institute for Transfusion Medicine, University of Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden- Wuerttemberg – Hessen, Germany; 4 Division of Immunology, Boston Children´s Hospital, Boston, USA; 5 Department of Pediatrics, University Hospital, Brescia, Italy; 6 Institute of Cellular Medicine, Newcastle University and Pediatric Immunology and HSCT, Great North Children´s Hospital, Newcastle upon Tyne; 7 Allergy Immunology and BMT Division, UCSF Benioff Children´s
    [Show full text]
  • AK2 Deficiency Compromises the Mitochondrial Energy Metabolism Required for Differentiation of Human Neutrophil and Lymphoid Lineages
    Citation: Cell Death and Disease (2015) 6, e1856; doi:10.1038/cddis.2015.211 OPEN & 2015 Macmillan Publishers Limited All rights reserved 2041-4889/15 www.nature.com/cddis AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages E Six1,2,13, C Lagresle-Peyrou1,2,13, S Susini1,2, C De Chappedelaine1,2, N Sigrist1,2, H Sadek1,2, M Chouteau1,2, N Cagnard3, M Fontenay4, O Hermine2,5, C Chomienne6,7, P Reynier8, A Fischer2,9,10, I André-Schmutz1,2, N Gueguen8 and M Cavazzana*,1,2,11,12 Reticular dysgenesis is a human severe combined immunodeficiency that is primarily characterized by profound neutropenia and lymphopenia. The condition is caused by mutations in the adenylate kinase 2 (AK2) gene, resulting in the loss of mitochondrial AK2 protein expression. AK2 regulates the homeostasis of mitochondrial adenine nucleotides (ADP, ATP and AMP) by catalyzing the transfer of high-energy phosphate. Our present results demonstrate that AK2-knocked-down progenitor cells have poor proliferative and survival capacities and are blocked in their differentiation toward lymphoid and granulocyte lineages. We also observed that AK2 deficiency impaired mitochondrial function in general and oxidative phosphorylation in particular – showing that AK2 is critical in the control of energy metabolism. Loss of AK2 disrupts this regulation and leads to a profound block in lymphoid and myeloid cell differentiation. Cell Death and Disease (2015) 6, e1856; doi:10.1038/cddis.2015.211; published
    [Show full text]
  • Congenital Neutropenia and Primary Immunodeficiency Diseases
    Critical Reviews in Oncology / Hematology 133 (2019) 149–162 Contents lists available at ScienceDirect Critical Reviews in Oncology / Hematology journal homepage: www.elsevier.com/locate/critrevonc Congenital neutropenia and primary immunodeficiency diseases T ⁎ Jonathan Spoora,b,c, Hamid Farajifarda,d, Nima Rezaeia,d,e, a Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran,Iran b Erasmus University Medical Centre, Erasmus University Rotterdam, Rotterdam, the Netherlands c Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Rotterdam, the Netherlands d Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran e Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran ARTICLE INFO ABSTRACT Keywords: Neutropenia is a dangerous and potentially fatal condition that renders patients vulnerable to recurrent infec- Neutropenia tions. Its severity is commensurate with the absolute count of neutrophil granulocytes in the circulation. In Congenital paediatric patients, neutropenia can have many different aetiologies. Primary causes make up but asmall Immunological deficiency syndromes portion of the whole and are relatively unknown. In the past decades, a number of genes has been discovered Genetic diseases that are responsible for congenital neutropenia. By perturbation of mitochondrial energy metabolism, vesicle trafficking or synthesis of functional proteins, these mutations cause a maturation arrest in myeloid precursor cells in the bone marrow. Apart from these isolated forms, congenital neutropenia is associated with a multi- plicity of syndromic diseases that includes among others: oculocutaneous albinism, metabolic diseases and bone marrow failure syndromes.
    [Show full text]
  • Newborn Screening Severe Combined Immunodeficiency T Cell Lymphopenia
    NEWBORN SCREENING SEVERE COMBINED IMMUNODEFICIENCY T CELL LYMPHOPENIA APHL Webinar May 11,2011 Lisa Kobrynski MD, MPH Section Chief: Allergy/Immunology Emory University Disclosures Baxter: PI in clinical trials sponsored by Baxter What is Severe Combined Immune Deficiency: SCID? A group of disorders caused by single gene defects resulting in a combined immune deficiency Estimated Prevalence: 1:50,00 to 1:100,000 (U.S) Ranges from 0.89 to 2.43 cases/100,000 live births Over 13 different genetic forms All have profound defects in T lymphocyte differentiation and function Some (not all) have defects in B cell and/or NK cell differentiation as well Affected individuals have severe defects in humoral and cellular immunity SCID: Clinical presentation Present in first 6 months Opportunistic infections PJP, CMV, RSV, adenovirus, Candida Chronic diarrhea - rotavirus, giardiasis Dermatitis – severe erythroderma Persistent thrush – candidal esophagitis Failure to thrive Absence of lymphoid tissue Sepsis - gram negatives Family history Why do newborn screening for SCID? Universally fatal without treatment Asymptomatic at birth Curative therapy is readily available for most Early treatment (HSCT before 3 months of age) improves outcomes, decrease morbidity, mortality (Probable savings in healthcare costs) Ideal screening test - very high sensitivity, high specificity Screening test can be done on newborn dried blood spots Test must be inexpensive Confirmatory tests are widely available Public Health Intervention Analytic
    [Show full text]
  • Gene Therapy for Primary Immunodeficiency Diseases: Should We Do It?
    Department of Pediatrics LSUHSC Gene Therapy for Primary Immunodeficiency Diseases: Should we do it? Lily E. Leiva, Ph.D. Associate Professor and Immunology Lab Director Department of Pediatrics, LSUHSC and Children’s Hospital Classic C’ IgM PMN P IgG Pathway B IgA IgE IL-4 CD40 IL-13 Extracell Alt C’ CD40L Pathogens C3b IL-5 Pathway Th2 E IL-3 Bacteria MHC-II Activation NK APC TCR Th0 (-) Treg CD40-CD40L IL-10 TGFβ IL-1 IL-12 IL-2 CT Virally Th1 infected Chemokines cells IFN- Intracell M Pathogens IFN- R M Recruitment Activation L.Leiva, 2012 Primary Immunodeficiency Diseases (PID) • Monogenic or complex genetic disorders that affect one or several components of the immune system and are present during the patient’s lifetime. • PIDs can present clinically at any age and some improve due to compensatory mechanisms, others get worse with age. Phenotype / Molecular / Genotype Diagnosis of Primary Immunodeficiencies IMMUNE CLINICAL GENE PROTEIN ABNORMALITIES PHENOTYPE Gene Receptor Neutrophils Infection abnormality Enzyme Complement Inflammation Antibodies Autoimmunity >200 Cytokine abnormalities Lymphocytes Allergy Protein-based and functional assays X-Linked PIDs X-CGD (CYBB) Defective microbicidal activity Lymphocytes and platelets defects Absence of T and NK cells Absence of B cells Lymphoproliferative disorder (SH2D1A) Defective Ig switch LAD (β integrin) Defective leukocyte adhesion Primary Immune Deficiencies: “Experiments of Nature” Dr. Robert Good 1922 - 2003 Founder of Modern Immunology In 1968 Performed the 1st successful human BM transplant Incidence of Some PIDs Selective IgA 1:500 XLA 1:100,000 DiGeorge 1: 66,000 SCID 1: 66,000 CGD 1:250,000 Overall 1: 10,000 • PID affect at least 10 million people worldwide.
    [Show full text]
  • Reticular Dysgenesis and Mitochondriopathy Induced By
    www.nature.com/scientificreports OPEN Reticular Dysgenesis and Mitochondriopathy Induced by Adenylate Kinase 2 Defciency with Atypical Presentation Lina Ghaloul-Gonzalez1,2*, Al-Walid Mohsen 1,2, Anuradha Karunanidhi1, Bianca Seminotti1, Hey Chong3, Suneeta Madan-Khetarpal1,2, Jessica Sebastian1, Catherine Walsh Vockley1, Miguel Reyes-Múgica 4, Mark T. Vander Lugt 5 & Jerry Vockley1,2 Reticular dysgenesis is an autosomal recessive form of severe combined immunodefciency (SCID) that usually manifests in newborns. It is a unique example of an immune defciency that is linked to dysfunctional mitochondrial energy metabolism and caused by adenylate kinase 2 (AK2) defciency. It is characterized by an early diferentiation arrest in the myeloid lineage, impaired lymphoid maturation, and sensorineural hearing loss. In this study, a novel AK2 homozygous mutation, c.622 T > C [p.Ser208Pro], was identifed in an Old Order Amish patient through whole exome sequencing. Functional studies showed that the patient’s cells have no detectable AK2 protein, as well as low oxygen consumption rate (OCR), extracellular acidifcation rate (ECAR) and proton production rate (PPR). An increased production of reactive oxygen species, mitochondrial membrane permeability, and mitochondrial mass, and decreased ATP production, were also observed. The results confrm the pathogenicity of the AK2 mutation and demonstrate that reticular dysgenesis should be considered in Amish individuals presenting with immune defciency. We also describe other pathophysiological aspects of AK2 defciency not previously reported. Reticular dysgenesis (RD) (MIM267500; aleukocytosis) is an autosomal recessive form of severe combined immunodefciency (SCID) resulting from defects in the adenylate kinase 2, AK2, gene located on chromosome 1p35.1. Mitochondrial dysfuntion appears to be unique to AK2 defciency among the immune defciencies1–3.
    [Show full text]
  • OMB No. 0925-0046, Biographical Sketch Format Page
    OMB No. 0925-0001 and 0925-0002 (Rev. 09/17 Approved Through 03/31/2020) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: CANDOTTI, Fabio eRA COMMONS USER NAME (credential, e.g., agency login): FCANDOTTI POSITION TITLE: Assoc. Prof. of Medicine, Head Physician, Division of Immunology and Allergy, Lausanne University Hospital, Switzerland EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.) Completion DEGREE Date FIELD OF STUDY INSTITUTION AND LOCATION (if applicable) MM/YYYY School of Medicine, University of Brescia, Italy MD 1987 Medicine Laboratory of Biotechnology, Univ. of Brescia, Italy Postdoctoral 1991-1992 Molecular biology Fellow Department of Pediatrics, University of Pavia, Italy Specialty 1992 Pediatrics Board Department of Pediatrics, University of Brescia, Italy Subspecialty 1996 Pediatric Allergy and Board Immunology National Cancer Institute, NIH, Bethesda, MD, USA Postdoctoral 1992-1994 Gene therapy Fellow National Human Genome Research Institute, NIH, Postdoctoral 1994-1996 Gene therapy Bethesda, MD, USA Fellow A. Personal Statement I have a long-standing interest in defining the cellular and molecular bases of immunodeficiency diseases and in the development of new therapeutic approaches for these disorders. Through research and clinical activity in this field, I have been able to contribute to the discovery of the genes responsible for immunodeficiencies (e.g. JAK3-deficiency and reticular dysgenesis) and to define important clinical features of these disorders, as well as some of the immunological mechanisms leading to disease in affected patients.
    [Show full text]